Body image disturbance (BID) is a self-perceived negative change in appearance and or function. Head and neck cancer is associated with BID since head and neck cancer (HNC) involves cosmetically and functionally important areas. BID in HNC patients is common and causes anxiety, depression, social isolation and decreased quality of life. Unfortunately, there is little information with regards to BID in HNC patients. Current research is limited by the lack of a HNC specific BID scale and instead relies on BID scales created for other cancer subsites. Thus, a measurement scale made specifically for BID in HNC patient is needed. The objective of this project is to create and validate a BID scale specific to HNC patients.
Arising in cosmetically and functionally critical areas, head and neck cancer and its treatments commonly cause life-altering changes in appearance, swallowing, and speaking. These changes affect body function and quality of life. Body image disturbance, a displeasing change in appearance or function noted by the patient, is common in head and neck cancer patients and causes stress, anxiety, and isolation in these patients. Unfortunately, there is not a lot of data on the topic. Treatments of body image disturbance for head and neck cancer patients remain unknown preventing us from providing patients with the best cancer care. This study will evaluate the effects of a type of therapy on body image disturbance in head and neck cancer patients undergoing surgery.
Delays in starting radiation after surgery for head and neck cancer disproportionately affect minorities and those of low socioeconomic status, causing increased mortality. The barriers that prevent the delivery of timely, equitable postoperative radiation remain unknown. This study seeks to identify the barriers to timely, equitable postoperative radiation following surgery for head and neck cancer.
This research will develop and test a nutrition-focused mobile-support program for head and neck cancer patients and their caregivers at the end of treatment.
Phase I: To guide system development, we will conduct interviews with 15 individuals with head and neck cancer and their caregivers to understand the nutritional challenges faced at the end of treatment. We will also recruit 35 oncology dietitians to complete online surveys to identify key caregiver nutritional support tasks and caregiver demands.
Phase II: After system development, we will recruit 33 head and neck cancer patients and their main supporters to pretest our nutrition support system. Participants will be asked to complete two surveys and a one-time clinic session. The clinic session will include information and resources about symptoms and concerns and after the visit, the program will provide follow-up resources and support online for one month. Lastly, we we will conduct individual/small group interviews with 10 head and neck health care providers to evaluate feasibility and recommendations for future system development.
The information from this study may help us to improve supportive care programs in the future to help others as they complete head and neck cancer treatment.
This is a study that looks at the use of anti-platelet therapy and chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). Anti-platelet therapy is the use of drugs that reduce the blood's ability to form clots. The overall goal of this study is to see if this therapy combination can increase the body's ability to fight the disease.
This is a phase 1b/2, open-label, multicenter trial designed to look at the safety and efficacy of a study drug called SD 101 when injected into a tumor and used in combination with intravenous (IV) pembrolizumab in subjects with metastatic melanoma or recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The Medical University of South Carolina will only participate in phase 2 of this study and will include up to 10 subjects. Participation in this study will include up to 40 visits to the research center over approximately 110 weeks.
This is for adults diagnosed with locally advanced oral cavity cancer.The purpose of this study is to look at the effectiveness of nivolumab in patients with oral cavity cancer that is amendable to surgery. Patients will have screening tests to determine eligibility. If eligible, subjects will have three to four doses of nivolumab prior to undergoing surgery. After surgery, subjects will enter a follow up period.
This study is for participants who have been diagnosed with head and neck cancer that requires surgery as well as post-operative radiation and possibly cisplatin. The investigational drug in this study is Pembrolizumab. Pembrolizumab is a medication that is currently being tested in multiple cancers. It works by turning on your immune system to recognize and fight your cancer. The purpose of this study is to test the safety and the benefit of adding pembrolizumab to treatment that participants will already be getting for their cancer. Participants can be expected to be in this study for up to 3 years.
This research study is for patients who have completed all scheduled surgery, chemotherapy and/or radiation therapy for their cancer within the last 6-12 months and are currently having some type of sleep disturbance. While there is no standard treatment for sleep disturbance for cancer survivors, people who do not take part in this study may take over-the-counter or prescription medications, receive cognitive behavioral therapy, or exercise as a means of attempting to manage their sleep problems.
Sleep disturbance, particularly insomnia, is a common problem for cancer survivors. Insomnia can be described as excessive daytime napping, difficulty falling asleep, difficulty staying asleep, or waking up earlier than you would like. Insomnia can increase fatigue, impair physical function, impair immune function, cause circadian rhythms (known as your biological clock) to be disrupted and decrease quality of life.
Because there is no ideal standard of care for effectively treating sleep problems in cancer survivors, the purpose of this study is to compare the effectiveness of three different treatments for improving sleep problems and determine which is best. The three treatments are yoga, survivorship health education, and cognitive behavioral therapy (CBT-I).
Study participation will be approximately 8 months.
This research study is for patients who have xerostomia (dry mouth) caused by radiation treatment received in the past for cancer.
The purposed of this study is to determine whether or not acupuncture can improve symptoms related to dry mouth due to head/neck radiotherapy.
Eligible participants will be randomized (assigned by a computer) to one of three groups: the standard of care group (group where usual care for dry mouth is given) or to one of two acupuncture groups. One of the acupuncture treatment approaches has not been studied in a large randomized trial and may not target symptoms. Each group is equally important in the trial. All groups play an important role in helping to determine if acupuncture helps decrease symptoms of dry mouth.
Participation will last up to 9 months. About 240 people will be enrolled in this trial.